|
Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells. Shares in Evgen Pharma were up 11% to 1.16 pence each in London on Monday before midday. The clinical stage drug development company developing sulforaphane-based medicines said the laboratory of Marjolein Geurts, neuro-oncologist at the Erasmus University Medical Centre has observed continuing activity of SFX-01 in GBM cells. ‘We have seen continued evidence of biological activity in patient-derived glioblastoma tissue,’ said Geurts. Evgen Pharma said the in vitro studies, which are supported by a grant awarded by the KWF Dutch Cancer Society for a €1.1 million project, are designed to investigate the activity of SFX-01 in preclinical GBM models. This work is to be followed by administration of SFX-01 to patients with GBM in a clinical investigator sponsored study. The scientific collaboration, which commenced in October 2023, will run for three years, generating data continuously throughout the period. ‘These early data triangulate with those seen by our other academic collaborators in Abbruzzo, Italy and Auckland, New Zealand,’ said Evgen Pharma Chief Executive Officer Huw Jones. ‘This is another major academic group observing these effects in tissue derived from a different population of GBM patients which gives us further confidence of SFX-01’s potential as a therapeutic option for glioblastoma, a disease with very high unmet medical needs which is devastating for patients and their carers.’ Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
